Featured Research

from universities, journals, and other organizations

Evidence Links Anemia Drugs With Leukemic Transformation In Patients With Primary Myelofibrosis

Date:
December 11, 2007
Source:
Mayo Clinic
Summary:
Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis.

Mayo Clinic researchers reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis. The results of the retrospective study, which sought to quantify the risk factors for leukemic transformation, were presented by lead author Jocelin Huang, M.D., at the American Society of Hematology's annual meeting.

Related Articles


"We believe this to be the first large systematic evaluation of the risk factors leading to leukemic transformation in primary myelofibrosis," says Dr. Huang, hematology researcher at Mayo Clinic. "And in the process, we discovered some unexpected results."

The researchers confirmed a number of clinical and laboratory variables that appeared to correlate with leukemic transformation. Independent risk factors for development of leukemia included peripheral blood blast (immature leukemia cells) levels greater than or equal to 3 percent; and a platelet count of less than 100x109/liter (L). The more surprising findings were that specific treatments also appeared to be related to leukemic transformation. Use of ESAs or danazol (a hormone with anemia-countering properties) were linked to later development of leukemia, independent of the blast or platelet levels.

Ayalew Tefferi, M.D., principal investigator of the study, and a Mayo Clinic hematologist, cautions that the current findings are based on retrospective observation and need to be validated in properly designed prospective studies. "While we cannot take these findings as an absolute, at the same time, they cannot be ignored," says Dr. Tefferi. "Treatment decisions regarding the use of ESAs in patients with primary myelofibrosis should carefully be evaluated."

He also points out that ESA treatment in patients with primary myelofibrosis has the potential to cause further enlargement of the spleen (a known complication of the disease).

The study evaluated the records of 311 Mayo Clinic patients, seen with primary myelofibrosis between 1976 and 2006. Of these patients, at an average follow-up of 27 months, 27 cases (9 percent) of leukemic transformation were documented.

Other factors appeared to contribute to the development of leukemia, including anemia, leukocytosis and peripheral blood monocyte count greater than or equal to 1x109/L (both are measures of elevated white blood cells), hypercatabolic symptoms (results of excess metabolism), a splenectomy and treatment with androgens (a type of hormones). However, they were not independent predictors.

Other Mayo Clinic researchers contributing to the study included Chin-Yang Li, M.D.; Ruben Mesa, M.D.; Wenting Wu, Ph.D.; Curtis Hanson, M.D.; and Animesh Pardanani, M.B.B.S., Ph.D.

Primary Myelofibrosis

Primary myelofibrosis, also called myelofibrosis, is a bone marrow disorder that disrupts the body's normal production of blood cells, and results in scarring in bone marrow. The scarring leads to anemia and enlargement of the spleen and liver. Myelofibrosis is characterized by an overproduction of white blood cells. While the mechanism is not precisely understood, the scarring (fibrosis) of the bone marrow is thought to be a reaction to the activity of these excess white blood cells.

Erythropoiesis-Stimulating Agents

Erythropoiesis is the production of red blood cells. Individuals that suffer from anemia have lower-than-normal levels of red blood cells. Anemia can cause severe fatigue, and is a side effect of a number of medications, including many chemotherapeutic agents.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Evidence Links Anemia Drugs With Leukemic Transformation In Patients With Primary Myelofibrosis." ScienceDaily. ScienceDaily, 11 December 2007. <www.sciencedaily.com/releases/2007/12/071210163416.htm>.
Mayo Clinic. (2007, December 11). Evidence Links Anemia Drugs With Leukemic Transformation In Patients With Primary Myelofibrosis. ScienceDaily. Retrieved March 27, 2015 from www.sciencedaily.com/releases/2007/12/071210163416.htm
Mayo Clinic. "Evidence Links Anemia Drugs With Leukemic Transformation In Patients With Primary Myelofibrosis." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210163416.htm (accessed March 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com
HIV Outbreak Prompts Public Health Emergency In Indiana

HIV Outbreak Prompts Public Health Emergency In Indiana

Newsy (Mar. 26, 2015) Indiana Gov. Mike Pence says he will bring additional state resources to help stop the epidemic. Video provided by Newsy
Powered by NewsLook.com
Indiana Permits Needle Exchange as HIV Cases Skyrocket

Indiana Permits Needle Exchange as HIV Cases Skyrocket

Reuters - US Online Video (Mar. 26, 2015) Governor Mike Pence declares the recent HIV outbreak in rural Indiana a "public health emergency" and authorizes a short-term needle-exchange program. Rough Cut (no reporter narration) Video provided by Reuters
Powered by NewsLook.com
AAA: Distracted Driving a Serious Teen Problem

AAA: Distracted Driving a Serious Teen Problem

AP (Mar. 25, 2015) While distracted driving is not a new problem for teens, new research from the AAA Foundation for Traffic Safety says it&apos;s much more serious than previously thought. (March 25) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins